Ramey & Schwaller, LLP v. EMED Technologies Corp. <b><font color="red"> ONLY Bio-Health Frontiers, Inc. claims are remanded to the 61st District Court of Harris County, Texas.</font></b>

CourtDistrict Court, S.D. Texas
DecidedNovember 8, 2021
Docket4:21-cv-02036
StatusUnknown

This text of Ramey & Schwaller, LLP v. EMED Technologies Corp. <b><font color="red"> ONLY Bio-Health Frontiers, Inc. claims are remanded to the 61st District Court of Harris County, Texas.</font></b> (Ramey & Schwaller, LLP v. EMED Technologies Corp. <b><font color="red"> ONLY Bio-Health Frontiers, Inc. claims are remanded to the 61st District Court of Harris County, Texas.</font></b>) is published on Counsel Stack Legal Research, covering District Court, S.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ramey & Schwaller, LLP v. EMED Technologies Corp. <b><font color="red"> ONLY Bio-Health Frontiers, Inc. claims are remanded to the 61st District Court of Harris County, Texas.</font></b>, (S.D. Tex. 2021).

Opinion

UNITED STATES DISTRICT COURT November 09, 2021 SOUTHERN DISTRICT OF TEXAS Nathan Ochsner, Clerk HOUSTON DIVISION

RAMEY & SCHWALLER, LLP, § § Plaintiff, § § VS. § CIVIL ACTION NO. 4:21-CV-02036 § EMED TECHNOLOGIES CORP., et al., § § Defendants. §

MEMORANDUM OPINION AND ORDER

I. INTRODUCTION

Pending before the Court is the plaintiff’s/counter-defendant’s, Ramey & Schwaller LLP (“Ramey”), combined motion to dismiss pursuant to Rule 12(b)(6) and motion to strike affirmative defenses pursuant to Rule 12(f). (DE 16). The defendants/counter-plaintiffs, EMED Technologies Corp. (“EMED”) and Bio-Health Frontiers, Inc. (“BHF”), have filed a response opposing the motion (DE 18), and Ramey has filed a reply in support (DE 19). After having carefully considered the parties’ submissions and the applicable authorities, the Court determines that Ramey’s motions should be DENIED. Additionally, the Court determines, sua sponte, that it lacks subject matter jurisdiction over the plaintiff’s suit against defendant BHF, only, and that the suit against BHF should be REMANDED, pursuant to 28 U.S.C. § 1447(c), to the 61st Judicial District Court of Harris County, Texas, where it was originally filed and assigned Cause No. 2021-31087. II. FACTUAL AND PROCEDURAL BACKGROUND

Ramey filed suit against the defendants in Texas state court, seeking to recover legal fees allegedly earned on a contingency basis for representing EMED in patent infringement litigation against Repro-Med Services, Inc. (“RMS”), and for related patent prosecution work. (DE 1). In the same filing, Ramey also sued BHF for unpaid legal fees and expenses incurred in unrelated matters. After removing the action to this Court, the defendants timely answered Ramey’s suit on August 27, 2019, asserting numerous affirmative defenses. (DE 10). In addition, EMED counter-claimed against Ramey for

legal malpractice arising out of Ramey’s patent prosecution work and two lawsuits brought by Ramey on EMED’s behalf against RMS. Specifically, EMED’s counter-claim against Ramey arises out of Ramey’s patent prosecution work and related litigation services involving two EMED patents—U.S. Patent No.’s 9,808,576 (the “‘576 Patent”) and 8,961,476 (the “‘476 Patent”). Ramey

originally prosecuted the ‘576 Patent in 2017 before the United States Patent and Trademark Office (USPTO). In doing so, Ramey agreed to amend a part of the primary claim under the patent with the term “consisting of,” instead of “including.” On November 7, 2017, Ramey sued RMS on EMED’s behalf in New York federal court for infringing the ‘576 Patent (the “New York Litigation”). At the claims construction

hearing in that suit, the court determined that EMED’s use of the “consisting of” patent language significantly limited the scope of the ‘576 Patent. On August 30, 2019, the court awarded summary judgment for RMS, and a magistrate judge later concluded that the New York Litigation was objectively baseless and warranted a sanction of approximately $1 million against EMED. In the case at bar, EMED alleges that Ramey committed professional negligence by pursuing what it knew, or should have known, was a baseless infringement theory in the New York Litigation, as well as by giving EMED false

assurances of success and needlessly incurring litigation fees and expenses. In a separate 2015 suit against RMS in the Eastern District of Texas (the “East Texas Litigation”), Ramey argued that RMS infringed the ‘476 Patent held by EMED. There, also, the district court granted summary judgment for RMS, which again sought sanctions against EMED for vexatious litigation. RMS’s sanctions motion was stayed

pending appeal of the summary judgment. After the Federal Circuit affirmed summary judgment for RMS, EMED sought en banc review. While the en banc petition was pending, EMED and RMS settled “all pending litigation.” EMED asserts, however, that its settlement amount was far lower than the amount Ramey represented EMED could expect to recover, and far lower than what a reasonably prudent patent attorney would

have been able to obtain. EMED now seeks actual and exemplary damages, costs, and attorney’s fees from Ramey through its legal malpractice claim. In response, Ramey filed a motion to dismiss part of EMED’s counterclaim under Rule 12(b)(6), as well as a motion to strike the defendant’s affirmative defenses under Rule 12(f).

III. THE PARTIES’ CONTENTIONS Ramey argues that Texas’s two-year limitations period for legal malpractice suits bars EMED’s counterclaim, to the extent the claim relates to any patent prosecution, opinion, and other “non-litigation” work performed by Ramey prior to August 27, 2019. Specifically, Ramey contends that Texas’s tolling rule for limitations periods pertaining to legal malpractice claims does not apply to what Ramey calls “non-litigation work” performed by Ramey prior to the New York or East Texas Litigation. According to

EMED, however, Ramey has failed to establish that the tolling rule does not apply to Ramey’s non-litigation work. Ramey also asserts that the defendants’ affirmative defenses should be struck because the defendants merely recited the defenses in their Original Answer and Counterclaim (DE 10) and failed to meet the “fair notice” requirement under Rule 12(f).

The defendants argue that Ramey fails to show that their affirmative defenses cannot, as a matter of law, succeed in any circumstance. The defendants also raise, but do not brief, the issue of whether the Court has subject matter jurisdiction over Ramey’s claim against BHF. IV. STANDARD OF REVIEW

a. Federal Rule of Civil Procedure 12(b)(6) Federal Rule of Civil Procedure 12(b)(6) authorizes a defendant to move to dismiss for “failure to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). Under the demanding strictures of a Rule 12(b)(6) motion, “[t]he plaintiff's complaint is to be construed in a light most favorable to the plaintiff, and the allegations contained therein are to be taken as true.” Oppenheimer v. Prudential Sec., Inc., 94 F.3d

189, 194 (5th Cir. 1996) (citing Mitchell v. McBryde, 944 F.2d 229, 230 (5th Cir. 1991)). Dismissal is appropriate only if, the “[f]actual allegations [are not] enough to raise a right to relief above the speculative level, on the assumption that all the allegations in the complaint are true (even if doubtful in fact).” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555, 127 S. Ct. 1955, 1965, 167 L. Ed.2d 929 (2007). Moreover, in light of Federal Rule of Civil Procedure 8(a)(2), where a plaintiff does not allege fraud or mistake, “[s]pecific

facts are not necessary; the [factual allegations] need only ‘give the defendant fair notice of what the . . . claim is and the grounds upon which it rests.” Erickson v. Pardus, 551 U.S. 89, 93, 127 S. Ct. 2197, 2200, 167 L. Ed.2d 1081 (2007) (per curiam) (quoting Twombly, 550 U.S. at 555, 127 S. Ct. at 1964). Even so, “a plaintiff’s obligation to provide the ‘grounds’ of his ‘entitle[ment] to relief’ requires more than labels and

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Oppenheimer v. Prudential Securities Inc.
94 F.3d 189 (Fifth Circuit, 1996)
Causey v. Sewell Cadillac-Chevrolet, Inc.
394 F.3d 285 (Fifth Circuit, 2004)
Cambridge Toxicology Group, Inc. v. Exnicios
495 F.3d 169 (Fifth Circuit, 2007)
Mendoza v. Murphy
532 F.3d 342 (Fifth Circuit, 2008)
Scheuer v. Rhodes
416 U.S. 232 (Supreme Court, 1974)
Papasan v. Allain
478 U.S. 265 (Supreme Court, 1986)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Frame v. City of Arlington
657 F.3d 215 (Fifth Circuit, 2011)
United States v. Oscar Renda
709 F.3d 472 (Fifth Circuit, 2013)
ERI Consulting Engineers, Inc. v. Swinnea
318 S.W.3d 867 (Texas Supreme Court, 2010)
Dunnagan v. Watson
204 S.W.3d 30 (Court of Appeals of Texas, 2006)
Johnson & Higgins of Texas, Inc. v. Kenneco Energy, Inc.
962 S.W.2d 507 (Texas Supreme Court, 1998)
Van Polen v. Wisch
23 S.W.3d 510 (Court of Appeals of Texas, 2000)
Cass v. Stephens
156 S.W.3d 38 (Court of Appeals of Texas, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Ramey & Schwaller, LLP v. EMED Technologies Corp. <b><font color="red"> ONLY Bio-Health Frontiers, Inc. claims are remanded to the 61st District Court of Harris County, Texas.</font></b>, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ramey-schwaller-llp-v-emed-technologies-corp-bfont-colorred-txsd-2021.